Use of 5-fluorocytosine in patients with impaired renal function.
The plasma level and elimination of 5-fluorocytosine (5-FC) was measured in normal subjects and patients with impaired renal function. Prolongation of the half-life of the drug in renal failure has been confirmed. Renal clearance of 5-FC was about 75% of the creatinine clearance and a corresponding modification of drug dosage should be made in patients with renal insufficiency.
D000935:Antifungal Agents / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D003596:Cytosine / Q000378:metabolism*; D005437:Flucytosine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000652:urine; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*
D000935:Antifungal Agents; D003596:Cytosine; D003404:Creatinine; D005437:Flucytosine